Nasdaq · CIK 0001048477
BMRN BIOMARIN PHARMACEUTICAL INC
Insider trading from SEC Form 4. Last filing 11 d ago. Close $54.80 on Oct 9, 2026, +10% from the 52-week low and -22% from the high.
Last 90 days
Net insider value
-$1.2M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
1
$1.2M by 1 insider
Insiders on file
18
with a Form 4 at this company
Price and insider trades, last year
BMRNOct 9, 2026 · close 54.80
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at BIOMARIN PHARMACEUTICAL INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 45Moderate | George Eric Davis EVP, Chief Legal Officer sell | $1.2M 17,557 shares | -22% | - | |
| 10Weak | Erin Burkhart GVP, Chief Accounting Officer sell | $106k 1,786 shares | -11% | +7% from low-29% from high | |
| 0Weak | Cristin Hubbard EVP, Chief Commercial Officer sell | $18k 273 shares | -1% | +11% from low-27% from high | |
| 13Weak | Erin Burkhart GVP, Chief Accounting Officer sell | $93k 1,295 shares | -7% | - | |
| 41Moderate | Charles Greg Guyer EVP, Chief Technical Officer sell | $501k 7,034 shares | -7% | - | |
| 12Weak | Erin Burkhart GVP, Chief Accounting Officer sell | $92k 1,344 shares | -9% | - | |
| 30Weak | Charles Greg Guyer EVP, Chief Technical Officer sell | $350k 5,278 shares | -7% | - |
Transactions
The last 55 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Gregory R Friberg EVP, Chief R&D Officer | FTax withholding Common Stock | -4,086 | $60.00 | $245k | 47,732 | 11 d ago |
| Sep 10, 2026 | Robert M Plenge director | AGrant or award Common Stock | +6,140 | $0.00 | $0 | 6,140 | 28 d ago |
| Sep 2, 2026 | George Eric Davis EVP, Chief Legal Officer | SOpen-market sale Common Stock | -17,557 | $66.28 | $1.2M | 61,003 | 39 d ago |
| Aug 1, 2025 | Ian T Clark director | AGrant or award Common Stock | +7,000 | $0.00 | $0 | 7,000 | Aug 5, 2025 |
| May 20, 2025 | Timothy P Walbert director | AGrant or award Common Stock | +6,650 | $0.00 | $0 | 9,780 | May 22, 2025 |
| May 20, 2025 | Cristin Hubbard EVP, Chief Commercial Officer | FTax withholding Common Stock | -2,155 | $59.93 | $129k | 30,545 | May 22, 2025 |
| May 20, 2025 | Richard A Meier director | AGrant or award Common Stock | +6,650 | $0.00 | $0 | 127,426 | May 22, 2025 |
| May 20, 2025 | Robert J. Hombach director | AGrant or award Common Stock | +6,650 | $0.00 | $0 | 41,870 | May 22, 2025 |
| May 20, 2025 | Maykin Ho director | AGrant or award Common Stock | +6,650 | $0.00 | $0 | 28,010 | May 22, 2025 |
| May 20, 2025 | Mark J Enyedy director | AGrant or award Common Stock | +6,650 | $0.00 | $0 | 13,550 | May 22, 2025 |
| May 20, 2025 | Willard H Dere director | AGrant or award Common Stock | +6,650 | $0.00 | $0 | 38,950 | May 22, 2025 |
| May 20, 2025 | Athena Countouriotis director | AGrant or award Common Stock | +6,650 | $0.00 | $0 | 13,550 | May 22, 2025 |
| May 20, 2025 | Barbara W. Bodem director | AGrant or award Common Stock | +6,650 | $0.00 | $0 | 13,555 | May 22, 2025 |
| May 20, 2025 | Elizabeth M Anderson director | AGrant or award Common Stock | +6,650 | $0.00 | $0 | 34,450 | May 22, 2025 |
| May 19, 2025 | Erin Burkhart GVP, Chief Accounting Officer | FTax withholding Common Stock10b5-1 | -996 | $59.27 | $59k | 15,959 | May 20, 2025 |
| May 20, 2025 | Erin Burkhart GVP, Chief Accounting Officer | SOpen-market sale Common Stock10b5-1 | -1,786 | $59.31 | $106k | 14,173 | May 20, 2025 |
| Apr 30, 2025 | Cristin Hubbard EVP, Chief Commercial Officer | AGrant or award Common Stock10b5-1 | +273 | $54.14 | $15k | 32,973 | May 6, 2025 |
| May 2, 2025 | Cristin Hubbard EVP, Chief Commercial Officer | SOpen-market sale Common Stock10b5-1 | -273 | $64.92 | $18k | 32,700 | May 6, 2025 |
| Mar 19, 2025 | Erin Burkhart GVP, Chief Accounting Officer | SOpen-market sale Common Stock10b5-1 | -1,295 | $71.52 | $93k | 16,955 | Mar 20, 2025 |
| Mar 14, 2025 | Erin Burkhart GVP, Chief Accounting Officer | FTax withholding Common Stock | -823 | $69.44 | $57k | 12,282 | Mar 18, 2025 |
| Mar 14, 2025 | George Eric Davis EVP, Chief Legal Officer | FTax withholding Common Stock | -16,249 | $69.44 | $1.1M | 69,975 | Mar 18, 2025 |
| Mar 14, 2025 | Charles Greg Guyer EVP, Chief Technical Officer | FTax withholding Common Stock | -20,127 | $69.44 | $1.4M | 67,528 | Mar 18, 2025 |
| Mar 14, 2025 | Brian Mueller EVP, Chief Financial Officer | FTax withholding Common Stock | -18,497 | $69.44 | $1.3M | 83,141 | Mar 18, 2025 |
| Mar 14, 2025 | Alexander Hardy Chief Executive Officer | FTax withholding Common Stock | -2,933 | $69.44 | $204k | 131,223 | Mar 18, 2025 |
| Mar 17, 2025 | Cristin Hubbard EVP, Chief Commercial Officer | AGrant or award Common Stock | +13,310 | $0.00 | $0 | 32,700 | Mar 18, 2025 |
| Mar 17, 2025 | Gregory R Friberg EVP, Chief R&D Officer | AGrant or award Common Stock | +17,750 | $0.00 | $0 | 46,810 | Mar 18, 2025 |
| Mar 17, 2025 | Gregory R Friberg EVP, Chief R&D Officer | AGrant or award Stock Option (Right to Buy Common Stock)derivative | +41,170 | $0.00 | $0 | 41,170 | Mar 18, 2025 |
| Mar 17, 2025 | Cristin Hubbard EVP, Chief Commercial Officer | AGrant or award Stock Option (Right to Buy Common Stock)derivative | +30,880 | $0.00 | $0 | 30,880 | Mar 18, 2025 |
| Mar 17, 2025 | George Eric Davis EVP, Chief Legal Officer | AGrant or award Common Stock | +12,940 | $0.00 | $0 | 82,915 | Mar 18, 2025 |
| Mar 17, 2025 | Alexander Hardy Chief Executive Officer | AGrant or award Common Stock | +44,360 | $0.00 | $0 | 175,583 | Mar 18, 2025 |
| Mar 17, 2025 | Erin Burkhart GVP, Chief Accounting Officer | AGrant or award Common Stock | +5,970 | $0.00 | $0 | 18,252 | Mar 18, 2025 |
| Mar 17, 2025 | Charles Greg Guyer EVP, Chief Technical Officer | AGrant or award Common Stock | +13,310 | $0.00 | $0 | 80,838 | Mar 18, 2025 |
| Mar 17, 2025 | Brian Mueller EVP, Chief Financial Officer | AGrant or award Common Stock | +16,640 | $0.00 | $0 | 99,781 | Mar 18, 2025 |
| Mar 17, 2025 | Brian Mueller EVP, Chief Financial Officer | AGrant or award Stock Option (Right to Buy Common Stock)derivative | +38,590 | $0.00 | $0 | 38,590 | Mar 18, 2025 |
| Mar 17, 2025 | Alexander Hardy Chief Executive Officer | AGrant or award Stock Option (Right to Buy Common Stock)derivative | +61,750 | $0.00 | $0 | 61,750 | Mar 18, 2025 |
| Mar 17, 2025 | Erin Burkhart GVP, Chief Accounting Officer | AGrant or award Stock Option (Right to Buy Common Stock)derivative | +9,230 | $0.00 | $0 | 9,230 | Mar 18, 2025 |
| Mar 17, 2025 | George Eric Davis EVP, Chief Legal Officer | AGrant or award Stock Option (Right to Buy Common Stock)derivative | +30,020 | $0.00 | $0 | 30,020 | Mar 18, 2025 |
| Mar 17, 2025 | Charles Greg Guyer EVP, Chief Technical Officer | AGrant or award Stock Option (Right to Buy Common Stock)derivative | +30,880 | $0.00 | $0 | 30,880 | Mar 18, 2025 |
| Mar 6, 2025 | Charles Greg Guyer EVP, Chief Technical Officer | SOpen-market sale Common Stock | -7,034 | $71.28 | $501k | 87,655 | Mar 7, 2025 |
| Feb 28, 2025 | Charles Greg Guyer EVP, Chief Technical Officer | FTax withholding Common Stock | -4,287 | $71.16 | $305k | 94,689 | Mar 4, 2025 |
| Feb 25, 2025 | George Eric Davis EVP, Chief Legal Officer | AGrant or award Common Stock | +11,040 | $0.00 | $0 | 67,197 | Feb 27, 2025 |
| Feb 25, 2025 | Brian Mueller EVP, Chief Financial Officer | AGrant or award Common Stock | +11,040 | $0.00 | $0 | 82,611 | Feb 27, 2025 |
| Feb 25, 2025 | Charles Greg Guyer EVP, Chief Technical Officer | AGrant or award Common Stock | +11,040 | $0.00 | $0 | 79,949 | Feb 27, 2025 |
| Feb 25, 2025 | Charles Greg Guyer EVP, Chief Technical Officer | AGrant or award Common Stock | +9,660 | $0.00 | $0 | 89,609 | Feb 27, 2025 |
| Feb 25, 2025 | George Eric Davis EVP, Chief Legal Officer | AGrant or award Common Stock | +9,660 | $0.00 | $0 | 76,857 | Feb 27, 2025 |
| Feb 25, 2025 | Brian Mueller EVP, Chief Financial Officer | AGrant or award Common Stock | +9,660 | $0.00 | $0 | 92,271 | Feb 27, 2025 |
| Feb 25, 2025 | George Eric Davis EVP, Chief Legal Officer | AGrant or award Common Stock | +9,367 | $0.00 | $0 | 86,224 | Feb 27, 2025 |
| Feb 25, 2025 | Charles Greg Guyer EVP, Chief Technical Officer | AGrant or award Common Stock | +9,367 | $0.00 | $0 | 98,976 | Feb 27, 2025 |
| Feb 25, 2025 | Brian Mueller EVP, Chief Financial Officer | AGrant or award Common Stock | +9,367 | $0.00 | $0 | 101,638 | Feb 27, 2025 |
| Feb 24, 2025 | Timothy P Walbert director | AGrant or award Common Stock | +3,130 | $0.00 | $0 | 3,130 | Feb 26, 2025 |
| Feb 24, 2025 | Erin Burkhart GVP, Chief Accounting Officer | SOpen-market sale Common Stock10b5-1 | -1,344 | $68.38 | $92k | 13,105 | Feb 25, 2025 |
| Oct 31, 2024 | Alexander Hardy Chief Executive Officer | AGrant or award Common Stock | +300 | $56.01 | $17k | 148,451 | Dec 3, 2024 |
| Nov 29, 2024 | Alexander Hardy Chief Executive Officer | FTax withholding Common Stock | -14,295 | $66.03 | $944k | 134,156 | Dec 3, 2024 |
| Oct 31, 2024 | Charles Greg Guyer EVP, Chief Technical Officer | AGrant or award Common Stock | +55 | $56.01 | $3,080 | 74,187 | Nov 14, 2024 |
| Nov 12, 2024 | Charles Greg Guyer EVP, Chief Technical Officer | SOpen-market sale Common Stock | -5,278 | $66.37 | $350k | 68,909 | Nov 14, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Elizabeth M Andersondirector
- Barbara W. Bodemdirector
- Erin BurkhartGVP, Chief Accounting Officer
- Ian T Clarkdirector
- Athena Countouriotisdirector
- George Eric DavisEVP, Chief Legal Officer
- Willard H Deredirector
- Mark J Enyedydirector
- Gregory R FribergEVP, Chief R&D Officer
- Charles Greg GuyerEVP, Chief Technical Officer
- Robert J. Hombachdirector
- Alexander HardyChief Executive Officer
- Maykin Hodirector
- Cristin HubbardEVP, Chief Commercial Officer
- Richard A Meierdirector
- Brian MuellerEVP, Chief Financial Officer
- Robert M Plengeofficer, director
- Timothy P Walbertdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.